Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS
- 596 Downloads
This study aims at developing poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-PCL) nanoparticulate system as an intracellular delivery vehicle for saquinavir, an anti-HIV protease inhibitor.
Materials and Methods
Saquinavir-loaded PEO-PCL nanoparticles were prepared by a solvent displacement process. The formed nanoparticles were characterized for size, surface charge, and surface presence of PEO chains. Cellular uptake and distribution of the nanoparticle was examined in THP-1 human monocyte/macrophage (Mo/Mac) cell line. Intracellular saquinavir concentrations were measured as a function of dose and duration of incubation.
The PEO-PCL nanoparticles had a smooth surface and spherical shape and showed a relatively uniform size distribution with a mean particle diameter of approximately 200 nm. The surface presence of PEO chains was confirmed by an increase in the –C–O–(ether) signature of the C1s spectra in electron spectroscopy for chemical analysis. Rapid cellular uptake of rhodamine-123 encapsulated PEO-PCL nanoparticles was observed in THP-1 cells. Intracellular saquinavir concentrations when administered in the nanoparticle formulation were significantly higher than from aqueous solution.
This study shows that PEO-PCL nanoparticles provide a versatile platform for encapsulation of saquinavir and subsequent intracellular delivery in Mo/Mac cells.
Key wordsintracellular delivery nanoparticles poly(ethylene oxide)-modified poly(epsilon-caprolactone) saquivanir THP-1 monocytes/macrophages
The authors thank Professor Robert Campbell for the access to particle size and zeta potential instrument and Ms. Sushma Kommareddy for the SEM analysis. Additionally, Dr. Lara Gamble’s help with the ESCA investigations at the NESAC/BIO is gratefully acknowledged. NESAC/BIO is supported by the National Institutes of Health grant EB-002027.
- 3.S. Gunaseelan, O. Deborah, L. Wan, M. J. Leibowitz, A. B. Rabson, S. Stein, and P. J. Sinko. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using novel protease inhibition assay. Bioconjug. Chem. 15:1322–1333 (2004).PubMedCrossRefGoogle Scholar
- 5.S. A. Costas Kaparissides, K. Kotti, and S. Chaitidou. Recent advances in novel drug delivery systems. AZojono-Journal of Nanotechnology Online 2:1–11 (2006).Google Scholar
- 10.A. R. Bender, H. von Briesen, J. Kreuter, I. B. Duncan, and H. Rubsamen-Waigmann. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40:1467–1471 (1996).PubMedGoogle Scholar
- 17.J. Batsis. Clinical pharmacology of protease inhibitors in HIV infection. Trinity Stud. Med. J. 1:60–65 (2000).Google Scholar
- 20.A. Bender, A. Immelmann, J. Kreuter, H. Rubsamen-Waigmann, and H. von Briesen. Nanoparticles as drug carriers for antiviral agents against HIV. Int. Conf. AIDS 11:64 (1996).Google Scholar
- 22.A. Janoly, N. Bleyzac, P. Favetta, M. C. Gagneu, Y. Bourhis, S. Coudray, I. Oger, and G. Aulagner. Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci. 780:155–160 (2002).Google Scholar